Drug Trial Radar · NCT04657991
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
257
Actual
Start
Jan 15, 2021
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encorafenib and binimetinib can continue until their melanoma is no longer responding. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Conditions
- Melanoma
Interventions
EncorafenibDrug
Encorafenib
BinimetinibDrug
Binimetinib
PembrolizumabDrug
Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead In (SLI): Incidence of Dose Limiting Toxicities (DLTs)Time frame: First 2 Cycles of Treatment (cycles are 21 days)
- Phase 3: Objective Response (OR) by Blinded Independent Central Review (BICR)Time frame: Time from the date of randomization until documented PD, start of subsequent anticancer therapy, or death due to any cause (approximately every 9 weeks).
Locations
151 sites in 27 countries. Site status is shown where the registry gives one.
AdventHealth Hematology and Oncology
Orlando, Florida
AdventHealth Orlando Infusion Center
Orlando, Florida
AdventHealth Orlando, Investigational Drug Services
Orlando, Florida
The University of Kansas Clinical Research Center
Fairway, Kansas
The University of Kansas Cancer Center - Overland Park
Overland Park, Kansas
KU Eye Center
Prairie Village, Kansas
The University of Kansas Cancer Center - Investigational Drug Services
Westwood, Kansas
The University of Kansas Cancer Center
Westwood, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Ophthalmic Consultants of Boston Inc (OCB)
Boston, Massachusetts
University of Cincinnati Medical Center
Cincinnati, Ohio
West Chester Hospital
West Chester, Ohio
Tennessee Oncology, PLLC
Dickson, Tennessee
Tennessee Oncology PLLC
Franklin, Tennessee
Tennessee Oncology PLLC
Gallatin, Tennessee
Tenessee Oncology, PLLC
Hendersonville, Tennessee
Tennessee Oncology PLLC
Hermitage, Tennessee
University of Tennessee Medical Center
Knoxville, Tennessee
Tennessee Oncology PLLC
Lebanon, Tennessee
Tennessee Oncology PLLC
Murfreesboro, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Tennessee Oncology PLLC
Nashville, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Tennessee Oncology, PLLC
Shelbyville, Tennessee
Tennessee Oncology PLLC
Smyrna, Tennessee
Instituto Alexander Fleming
CABA, Buenos Aires, Argentina
Clinica Viedma S. A
Viedma, Río Negro Province, Argentina
Medizinische Universität Graz
Graz, Austria
Cliniques universitaires Saint-Luc
Brussels, Belgium
Hospital Sírio-Libanês - Unidade Bela Vista
São Paulo, Brazil
Instituto de Oncologia do Paraná - IOP Matriz Mateus Leme
Curitiba, Paraná, Brazil
Instituto de Oncologia do Paraná - IOP Oncoville
Curitiba, Paraná, Brazil
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil
Complex Oncology Center - Plovdiv EOOD
Plovdiv, Bulgaria
Medical Center Nadezhda Clinical EOOD
Sofia, Bulgaria
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.